GPRC5A and neoplasm: GPCRs are considered to be amongst the best drug targets for many diseases, and therefore, GPRC5A represents a new opportunity to exploit the notion of “conditional synthetic lethality”—leveraging the cancer‐associated nature of hypoxia to selectively target tumour cells for death.